If you have any questions for next week's webinar guest speakers (Pyx Resources, Helix Exploration, Fulcrum Metals and Metals One), please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBio-Sustainable Future Enterprises Regulatory News (BSFA)

Share Price Information for Bio-Sustainable Future Enterprises (BSFA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.25
Bid: 5.00
Ask: 5.50
Change: 1.00 (23.53%)
Spread: 0.50 (10.00%)
Open: 4.25
High: 5.25
Low: 4.25
Prev. Close: 4.25
BSFA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK’s First Fillet of Cultivated Meat Produced

1 Feb 2023 07:00

RNS Number : 5477O
BSF Enterprise PLC
01 February 2023
 

 

 

BSF Enterprise PLC

("BSF" or the "Company")

 

UK's First Full-Scale Fillet of Cultivated Meat Produced

 

The Lab-Grown Pork Fillet Represents a Scientific Breakthrough which Exceeds Expectations in Appearance, Taste and Texture

 

BSF Enterprise plc, an investment company focused on unlocking the next generation of biotech solutions, announces that its wholly owned subsidiary, 3D Bio-Tissues (3DBT), has successfully produced the UK's first steak fillet of structured cultivated meat in its Newcastle-based laboratory. The fillet of pork was subsequently cooked and eaten by 3D Bio-Tissues' management team.

 

The fillet was produced using 3DBT's patented, serum-free and animal-free cell booster, City-mixTM which eliminated the requirement of conventional plant-based scaffolds, blends or fillers, as have been universally adopted by the industry to date to ensure structural integrity of cultivated meat products. 3DBT's fillet is therefore 100% meat, leading the Company to believe this is the world's first 100% cultivated pork steak to be produced.

 

This represents a significant development milestone and following the success of the technical tests and the identification of development areas, 3DBT will forge ahead in producing a showcase product - a full-scale fillet of cultivated pork which will be presented, cooked, and eaten at a public event in the coming months.

 

A video of the meat being cooked can be viewed below:

 

Your browser does not support HTML5 video.

The process

 

3DBT used porcine cells to produce the cultivated pork fillet, measuring 9 cm width, 4 cm in length and 1 cm in height, making it similar in size to a small fillet of traditional meat. The fillet was replicated to pork's unique flavour and texture.

 

The process of producing the fillet began by extracting cells from a pig and putting them in a cell-culture environment, which allowed them to grow and divide. The cells were then cultivated using the company's proprietary structured meat technology along with their patented cell-boosting supplement City-mixTM to turn the cells into structured meat.

 

City-mixTM, a standalone commercially available product, enables the reduction of the use of expensive growth factors whilst increasing yield. Its use enhances the growth of cells and tissues to the point that the need for a scaffold is eliminated. City-mixTM is a critical intellectual property component of the Company's offering, providing clear competitive differentiation and world-leading technology.

 

Tasting and testing

 

3DBT'S Chief Executive Officer, Dr. Che Connon, and Chief Science Officer, Dr. Ricardo Gouveia, tested the fillet in the lab for various qualities in both its raw and cooked states and, for the first time, sampled the product in order to test its similarity to eating conventional meat.

 

In its raw state the cultivated steak fillet was very similar in appearance to conventional meat with fibres clearly visible. On cutting the fillet, it displayed similar structural integrity to raw conventional meat, including resistance to breaking and compression. In addition, it was the same to the touch in terms of consistency and elasticity and, as with fresh traditional meat, had no obvious aroma while raw.

 

On pan-frying, the fillet was cooked through and exhibited an element of shrinkage, as would be expected with high-quality traditional meat. The fillet seared easily, showing the typical browning, charring and crisping on its surface, and the aromas were identical to those of frying traditional pork.

 

When eating the cooked meat, it was found to exhibit very similar texture, consistency and flavour to that of traditional pork. In summary, the test results exceeded expectations in all respects. The testers agreed that both the texture and the taste in the mouth was indistinguishable from pork steak. The texture being a direct consequence of the unique cell-growth and tissue-templating process employed by 3DBT.

 

Next steps

 

3DBT now plans to take the findings from this to produce a further fillet to be showcased publicly outside of the lab environment and for third-party individuals to taste the produce. In the next phase, 3DBT plan to build upon the [structural integrity] already delivered.

 

Dr. Che Connon, Chief Executive of 3DBT, said: "This is a significant scientific breakthrough which has very positive implications not just for BSF and 3DBT but also for the UK and the cultivated meat industry as a whole. We are absolutely delighted with the look, taste and texture of our cultivated pork, which is the first time we have fully sampled our product. Our cruelty-free fillet has exceeded our expectations in all respects, and we are extremely excited about the technological progress we are making and the impact this could have upon our industry.

 

"City-mixTM, our serum free media in which we cultivated the fillet, is helping to greatly reduce the cost of cultivated meat such that it may become economically viable in the near future. At the same time our 'structure without scaffold' technology is helping to make cultivated meat that more closely resembles traditional meat in every respect, without the need for plant-based additives. We look forward to taking the findings through to the next stage of development, focused on producing a chef-ready product for public consumption."

 

  For further enquiries, please visit www.bsfenterprise.com or contact:

 

 

BSF Enterprise PLC

 

 

Via SEC Newgate below

Geoff Baker - Non-Executive Director

Che Connon - Executive Director

 

Shard Capital (Broker)

Damon Heath

0203 971 7000

 

SEC Newgate (Financial Communications)

Bob Huxford

Elisabeth Cowell

George Esmond

020 3757 6882

BSF@secnewgate.co.uk

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSSISMFEDSEDE
12
Date   Source Headline
18th Jun 20247:00 amRNSDirector/PDMR Shareholding
17th Jun 20247:00 amRNSDirector/PDMR Shareholding
14th Jun 202410:47 amRNSDirector/PDMR Shareholding
13th Jun 20247:00 amRNSGrant of Options
11th Jun 20247:00 amRNSInterim Results
11th Apr 20247:00 amRNSSuccessful Cultivated Leather PoC Agreements
20th Mar 202412:56 pmRNSResult of Annual General Meeting
20th Mar 202410:19 amRNSUniversity Collaborations
14th Mar 20247:00 amRNSInvestor Evening
7th Mar 20247:00 amRNSBSF Enterprise and Ivy Farm Enter Partnership
29th Feb 20247:00 amRNSMoU with Sustainable Fashion Company
26th Feb 20247:27 amRNSNotice of AGM
22nd Feb 20247:00 amRNSKerato Limited - Update
15th Feb 20247:00 amRNSStrategic Update
31st Jan 20247:00 amRNSFull Year Results
8th Dec 20237:00 amRNSFOODTECH Joint Venture with CellRev
30th Nov 20233:07 pmRNSStandard form for notification of major holdings
24th Nov 20237:00 amRNS3D Bio-Tissues Product Partnership Progress
26th Oct 20237:00 amRNSNew Cornea Company & Investor Update
9th Oct 20239:34 amRNSParticipation in The ThinkEquity Conference
26th Sep 20232:32 pmRNSResults of General Meeting & Allotment of Shares
18th Sep 20237:00 amRNS3D Bio-Tissues receives EUR612,000 grant
11th Sep 20237:00 amRNSStrategic Update
7th Sep 20239:46 amRNSPublication of Prospectus & Notice of GM
17th Jul 20237:00 amRNSCity-Mix Bio-Pharmaceutical Update
3rd Jul 20239:56 amRNSOpens Office in Hong Kong
29th Jun 20237:00 amRNSInterim Results
23rd Jun 202311:30 amRNSCultivated Meat Approved for Consumption in US
8th Jun 20237:00 amRNSUS Investor Roadshow & Appointment of US IR Agency
1st Jun 20237:00 amRNSPublication of New Research
30th May 20237:00 amRNSSuccessful Cultivated Meat Test
25th May 20237:00 amRNSAdmittance to trading on the OTCQB Venture Market
22nd May 20237:00 amRNSCommercial Progress Update
15th May 20237:00 amRNSLab-Grown Leather Update and Innovation Award Win
21st Apr 20237:00 amRNSShowcase Meat Update
14th Apr 20238:00 amRNSAdmission of Placing Shares & Subscription Shares
12th Apr 20233:35 pmRNSUpdate to Oversubscribed £2.9 million fundraise
29th Mar 20234:35 pmRNSPrice Monitoring Extension
29th Mar 20237:00 amRNSOversubscribed £2.9 million fundraise
15th Mar 202311:59 amRNSResult of Annual General Meeting
15th Mar 20237:00 amRNSAGM Statement
9th Mar 20238:53 amRNSApplication for Trading on US OTCQB Venture Market
6th Mar 20237:00 amRNSCity-Mix Commercial Progress Update
20th Feb 20233:00 pmRNSNotice of AGM
10th Feb 20237:00 amRNSAllotment of shares
1st Feb 20234:40 pmRNSSecond Price Monitoring Extn
1st Feb 20234:35 pmRNSPrice Monitoring Extension
1st Feb 20232:05 pmRNSSecond Price Monitoring Extn
1st Feb 20232:00 pmRNSPrice Monitoring Extension
1st Feb 20237:00 amRNSUK’s First Fillet of Cultivated Meat Produced
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.